Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial.
Davey RT Jr, Collins GL, Rouphael N, Poliquin G, McConnell R, Grubbs G, Moir SL, Langley JM, Teitelbaum M, Hewlett AL, McLellan SLF, Bhadelia N, Raabe VN, Mulligan MJ, Maljkovic Berry I, Dighero-Kemp B, Kurtz JR, Hensley LE, Dozier NCE, Marron LCB, DuChene A, Kuhn JH, Brown SK, Khurana S, Lane HC, Neaton JD. Davey RT Jr, et al. Among authors: kuhn jh. Lancet Microbe. 2024 Nov;5(11):100923. doi: 10.1016/S2666-5247(24)00163-0. Epub 2024 Oct 4. Lancet Microbe. 2024. PMID: 39374605 Free article. Clinical Trial.
Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial.
Valayer S, Alexandre M, Prague M, Beavogui AH, Doumbia S, Kieh M, Greenwood B, Leigh B, Poupelin M, Schwimmer C, Sow SO, Berry IM, Kuhn JH, Fusco D, Cauwelaert ND, Watson-Jones D, Thiébaut R, Lévy Y, Yazdanpanah Y, Richert L, Lhomme E; PREVAC Study Team; Aboulhab J, Aguirre-MacKenzie M BS, Akoo P MB, ChB, Akpa E MSN, MPH, RN, Akpata R, Albert S BA, MPH, Ale BM MD, MSc, MPH, Alimamy-Bangura S MB, ChB, Andong P MSt, Andrews BC, Anoma S, Atri N MPH, CPH, Augier A MCom, Awuondo K MSc, Ayouba A, Badio M MSc, Bagayoko A, Balde A MPH, Balssa J PharmD, Bangura LM BSc, Barrington K MPA, Barte de Saint Fare E BA, Baseler B MS, Bauder A BA, PMP, Bauduin C MSc, Bawo L MSc, Beavogui AH MD, PhD, Belson M BS, Ben-Farhat S MEng, Bererd M BS, Bernaud N MSc, Beyslow T PharmD, Biai N MSc, Billioux J, Billouin-Frazier S MSc, Binachon B MD, MPH, Blie J MSc, Bockstal V, Boison P MS, Bolay F, Boly A MM, Bonawitz RE MD, MS, Borg AG MCM, Bosompem S PharmD, MSc, Bozman C MSc, Brady T MPH, Browne S RN, BSN, Bullis R. Valayer S, et al. Among authors: kuhn jh. Emerg Microbes Infect. 2025 Dec;14(1):2432353. doi: 10.1080/22221751.2024.2432353. Epub 2024 Dec 9. Emerg Microbes Infect. 2025. PMID: 39559990 Free PMC article. Clinical Trial.
Vector induced humoral responses after rVSVΔG-ZEBOV-GP immunization identify vaccinated individuals and correlate with Ebola virus glycoprotein antibodies.
Chandrasekaran P, Berry IM, Callier V, Anthony SM, Hensley K, Kuhn JH, Shaw-Saliba K, Kennedy SB, Kieh M, Browne SM, Crozier I, Davey RT, Lane HC, Hensley LE, Follmann DA. Chandrasekaran P, et al. Among authors: kuhn jh. J Infect Dis. 2024 Dec 24:jiae632. doi: 10.1093/infdis/jiae632. Online ahead of print. J Infect Dis. 2024. PMID: 39718991
A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs.
Carey BD, Yu S, Geiger J, Ye C, Huzella LM, Reeder RJ, Mehta M, Hirsch S, Bernbaum R, Cubitt B, Pahar B, Anthony SM, Marketon A, Bernbaum JG, Tran JP, Crozier I, Martínez-Sobrido L, Worwa G, de la Torre JC, Kuhn JH. Carey BD, et al. Among authors: kuhn jh. NPJ Vaccines. 2024 Nov 17;9(1):220. doi: 10.1038/s41541-024-01012-w. NPJ Vaccines. 2024. PMID: 39551823 Free PMC article.
Changes to virus taxonomy and the ICTV Statutes ratified by the International Committee on Taxonomy of Viruses (2024).
Simmonds P, Adriaenssens EM, Lefkowitz EJ, Oksanen HM, Siddell SG, Zerbini FM, Alfenas-Zerbini P, Aylward FO, Dempsey DM, Dutilh BE, Freitas-Astúa J, García ML, Hendrickson RC, Hughes HR, Junglen S, Krupovic M, Kuhn JH, Lambert AJ, Łobocka M, Mushegian AR, Penzes J, Muñoz AR, Robertson DL, Roux S, Rubino L, Sabanadzovic S, Smith DB, Suzuki N, Turner D, Van Doorslaer K, Vandamme AM, Varsani A. Simmonds P, et al. Among authors: kuhn jh. Arch Virol. 2024 Nov 3;169(11):236. doi: 10.1007/s00705-024-06143-y. Arch Virol. 2024. PMID: 39488803 Free PMC article.
Global remodeling of ADP-ribosylation by PARP1 suppresses influenza A virus infection.
Zhang Z, Uribe I, Davis KA, McPherson RL, Larson GP, Badiee M, Tran V, Ledwith MP, Feltman E, Yú S, Caì Y, Chang CY, Yang X, Ma Z, Chang P, Kuhn JH, Leung AKL, Mehle A. Zhang Z, et al. Among authors: kuhn jh. bioRxiv [Preprint]. 2024 Sep 19:2024.09.19.613696. doi: 10.1101/2024.09.19.613696. bioRxiv. 2024. PMID: 39345583 Free PMC article. Preprint.
Promotion of order Bunyavirales to class Bunyaviricetes to accommodate a rapidly increasing number of related polyploviricotine viruses.
Kuhn JH, Brown K, Adkins S, de la Torre JC, Digiaro M, Ergünay K, Firth AE, Hughes HR, Junglen S, Lambert AJ, Maes P, Marklewitz M, Palacios G, Sasaya 笹谷孝英 T, Shi 施莽 M, Zhang 张永振 Y-Z, Wolf YI, Turina M. Kuhn JH, et al. J Virol. 2024 Oct 22;98(10):e0106924. doi: 10.1128/jvi.01069-24. Epub 2024 Sep 20. J Virol. 2024. PMID: 39303014
328 results